- Home
- SYRE
as of 02-05-2026 3:56pm EST
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 2.6B | IPO Year: | 2016 |
| Target Price: | $56.50 | AVG Volume (30 days): | 569.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.91 - $35.31 | Next Earning Date: | 02-26-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -161873000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Spyre Therapeutics Inc. (SYRE)
Chief Executive Officer
Avg Cost/Share
$32.35
Shares
15,000
Total Value
$492,045.15
Owned After
671,583
Chief Executive Officer
Avg Cost/Share
$31.55
Shares
15,000
Total Value
$460,134.12
Owned After
671,583
Chief Executive Officer
Avg Cost/Share
$29.28
Shares
15,000
Total Value
$435,355.50
Owned After
671,583
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Turtle Cameron | SYRE | Chief Executive Officer | Feb 2, 2026 | Sell | $32.35 | 15,000 | $492,045.15 | 671,583 | |
| Turtle Cameron | SYRE | Chief Executive Officer | Jan 2, 2026 | Sell | $31.55 | 15,000 | $460,134.12 | 671,583 | |
| Turtle Cameron | SYRE | Chief Executive Officer | Dec 1, 2025 | Sell | $29.28 | 15,000 | $435,355.50 | 671,583 |
Compare SYRE vs Leading Stocks
See how SYRE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SYRE Spyre Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.